The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy

MeSH terms

• Antineoplastic Agents / therapeutic use
• Chromosome Aberrations*
• Codon
• Disease Progression
• Drug Resistance, Neoplasm / genetics*
• Fusion Proteins, bcr-abl / genetics*
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
• Mutation*
• Protein Kinase Inhibitors / therapeutic use